Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  larotaxel
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-8 of 8 for your search:
Start Over
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC6596, EUDRACT: 2006-003086-14, NCT00417209
Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC6668, EUDRACT: 2007-001943-23, NCT00625664
Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TCD6511, EudraCT:2006-006474-21, NCT00327743
Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC6088, XRP9881B/2001, EUDRACT : 2004-000572-14, NCT00087958
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TCD6595, XRP9881, NCT00386685
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TCD10037, XRP9881, NCT00387907
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC10073, EudraCT 2006-006473-24, NCT00485979
Phase I Study of RPR 109881A (a Taxoid Derivative) Administered as a Weekly 1-Hour Intravenous Infusion for Advanced Solid Tumors (Summary Last Modified 07/98)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: CAN-NCIC-IND101, NCI-V96-1096, IND101
Start Over